RxDoctor Payments Data

Thaddeus Temple, MD

Internal Medicine · New Orleans, LANPI 1801854161

Payments from drug & device makers

$3,074in general payments, 2019–2025

Across 170 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$924
  • Lilly USA, LLC$330
  • Boehringer Ingelheim$236
  • E.r. Squibb & Sons, L.L.C.$201
  • Novo Nordisk$185
  • Novartis$163
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,074 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$15,075
Medicare patients
55
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate217$192,914
MounjaroTirzepatide87$101,853
EliquisApixaban52$58,422
JardianceEmpagliflozin54$54,455
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$48,220
OzempicSemaglutide40$45,867
TrulicityDulaglutide21$25,036
RybelsusSemaglutide19$24,786
TradjentaLinagliptin19$20,708
Lantus SolostarInsulin Glargine,hum.Rec.Anlog120$18,895
LinzessLinaclotide24$18,233
EntrestoSacubitril/Valsartan15$18,212
SymbicortBudesonide/Formoterol Fumarate31$11,241
XareltoRivaroxaban20$11,195
Levemir FlexpenInsulin Detemir25$6,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$99$192,914217 claims
Lilly USA, LLCMounjaro, Trulicity$330$126,889108 claims
Boehringer IngelheimJardiance, Tradjenta$236$75,16373 claims
Novo NordiskOzempic, Rybelsus$185$70,65459 claims
PfizerEliquis$124$58,42252 claims
GSKTrelegy Ellipta$924$48,22059 claims
AbbVieLinzess$66$18,23324 claims
NovartisEntresto$163$18,21215 claims
AstraZenecaSymbicort$88$11,24131 claims
Johnson & JohnsonXarelto$14$11,19520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →